Delix Therapeutics raises $100M Series C to advance Zalsupindole into Phase II
Delix Therapeutics closed an oversubscribed $100M Series C led by Johnson & Johnson Innovation – JJDC and SV Health Investors’ Dementia Discovery Fund to support depression trials and development of its broader neuroplastogen pipeline.
- Raised
- $100M
- Round
- Series C
- Investors
- 12
- Investors
- Johnson & Johnson Innovation – JJDC, Inc.SV Health Investors’ Dementia Discovery Fund (DDF)RA CapitalUC InvestmentsArtis VenturesOMX VenturesDolby Family VenturesBail CapitalAdage Capital ManagementHamilton Square Partners ManagementVestal Point CapitalYK Bioventures
- Target market
- Patients with neuropsychiatric and neurological disorders
- Use of funds
- Advancing Zalsupindole through Phase IIb proof of concept, supporting additional pipeline candidates and clinical trials, and expanding neurological and neurodegenerative programs
Get started
Create a free account to read the full story.
Quick Answers
What is the latest news about Delix Therapeutics?
Delix Therapeutics closed an oversubscribed $100M Series C led by Johnson & Johnson Innovation – JJDC and SV Health Investors’ Dementia Discovery Fund to support depression trials and development of its broader neuroplastogen pipeline.
What does Delix Therapeutics do?
Delix Therapeutics is a Boston, MA-based clinical-stage neuroscience company focused on discovering and developing neuroplastogens for difficult-to-treat neuropsychiatric and neurological disorders.
How much did Delix Therapeutics raise?
Delix Therapeutics raised $100M in its Series C.
Who invested in Delix Therapeutics?
Investors named in this Series C include Johnson & Johnson Innovation – JJDC, Inc., SV Health Investors’ Dementia Discovery Fund (DDF), RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures and Bail Capital and 4 others.
How will Delix Therapeutics use the funding?
Delix Therapeutics plans to use the money for advancing Zalsupindole through Phase IIb proof of concept, supporting additional pipeline candidates and clinical trials, and expanding neurological and neurodegenerative programs.
Where is Delix Therapeutics based?
Delix Therapeutics is based in USA.
Who are the key people at Delix Therapeutics?
Key people named in this report: Mark Rus (Chief Executive Officer).